Company: HRTX
Filing Date: 2025-09-09
Form Type: S-3
Source: 0000950170-25-113834
Chunk: 29

Company: HERON THERAPEUTICS, INC. /DE/
Filing Date: 2025-09-09
Form: S-3
Chunk 29
---
ive or conversion rights. There are no redemption or sinking fund provisions applicable to the Common Stock. All outstanding shares of Common Stock are fully paid and non-assessable.

Transfer Agent and Registrar. The transfer agent and registrar for our common stock is Computershare Trust Company N.A.

Listing.Our common stock is currently listed on The Nasdaq Capital Market under the symbol “HRTX”.

Preferred Stock

Series A Convertible Preferred Stock

Designation and Amount.A total of 524,141 shares of Series A Convertible Preferred Stock are issued under the Certificate of Designation of Rights, Preferences and Privileges (the “Certificate of Designation for Series A Convertible Preferred Stock”) of Series A Convertible Preferred Stock, filed with the Secretary of State of the State of Delaware on August 11, 2025. The shares of Series A Convertible Preferred Stock have a stated value of $15.00 per share and are convertible into shares of Common Stock at a conversion price of $1.50 per share, subject to certain adjustments.

Dividends.Holders of Series A Convertible Preferred Stock are entitled to dividends on an as-if-converted basis in the same form as any dividends actually paid on shares of Common Stock or other securities of the Company.

Ranking.The Series A Convertible Preferred Stock will rank senior to Common Stock with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company.

<div align='center'>17</div>

Voting Rights.Except as otherwise required by law, the holders of Series A Convertible Preferred Stock have no right to vote on matters submitted to a vote of the Company’s stockholders. Without the prior written consent of a majority of the outstanding shares of Series A Convertible Preferred Stock, the Company may not: (i) amend its Certificate of Incorporation (including the Certificate of Designation for Series A Convertible Preferred Stock) in a manner adverse to the Series A Convertible Preferred Stock; (ii) create or authorize the creation of any other security convertible into or exercisable for any equity security ranking as to dividends, redemption or distribution of assets upon a liquidation senior to, the Series A Convertible Preferred Stock, or increase the authorized number of shares of Series A Convertible Preferred Stock; or (iii) enter into any agreement with respect to any of the foregoing.

Conversion. Upon receipt of Stockholder Approval, each share of Series A Convertible Preferred Stock will, without any further action on the